Trending News

Celgene, say goodbye to Otezla: BMS agrees to sell

With the Federal Trade Commission (FTC) sweating the details of Bristol-Myers Squibb and Celgene’s p
Read More

Bristol-Myers Squibb's Opdivo misses its shot at e

Bristol-Myers Squibb’s Opdivo already boasts an FDA approval in liver cancer patients who have been
Read More

GSK wins speedy FDA Zejula review in ovarian cance

GlaxoSmithKline has been working to restrengthen in cancer, particularly through a multibillion-doll
Read More

NHS to open young people’s gambling addiction serv

NHS England has announced the opening of a new gambling clinic for children and young people, as par
Read More

FDA Priority Review granted for GSK’s Zejula

The US Food and Drug Administration (FDA) has accepted Glaxo Smith Kline’s application for Zejula (n
Read More

Almirall takes option on Dermira’s eczema drug leb

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug leb
Read More

After Roche, BMS surprises, what does AbbVie need

With mergers and acquisitions come antitrust reviews. And with the U.S. Federal Trade Commission (FT
Read More


;